Endoscopy

AdaptivEndo™ and Plasmapp Collaborate to Develop Sterilization Techniques for Flexible Endoscopy

Retrieved on: 
Monday, November 20, 2023
Research, Medical Devices, Medical Supplies, Hospitals, Practice Management, Biotechnology, General Health, Health, Science, Other Science, Steam, Plasma, Multimedia, KAIST, FDA, Laboratory, Disinfectant, Sterilization, HLD, Growth, PlasMapper, Endoscopy, Medical device

AdaptivEndo™ and Plasmapp are working together to evaluate the use of low-temperature hydrogen peroxide gas plasma for various flexible endoscopy applications.

Key Points: 
  • AdaptivEndo™ and Plasmapp are working together to evaluate the use of low-temperature hydrogen peroxide gas plasma for various flexible endoscopy applications.
  • The initial focus of the evaluation is the AdaptivEndo™ GI endoscope platform, which utilizes a reposable handpiece (hybrid endoscopy).
  • We had been seeking alternatives to HLD and steam sterilization when we found the Plasmapp solutions at a trade show in Germany last year,” AdaptivEndo™ President, Ed Fancher said.
  • The relationship with AdaptivEndo™ allowed us to explore the potential applications within flexible endoscopy, specifically GI endoscopy.”
    Plasmapp stands at the forefront of plasma technology innovation.

L&T Technology Services Collaborates With NVIDIA to Unveil Gen AI and Advanced Software-Defined Architecture for Medical Devices

Retrieved on: 
Monday, November 20, 2023
Software, Biotechnology, Hardware, Health, Artificial Intelligence, Medical Devices, Health Technology, Technology, Classification, Senior, L&T Technology Services, Polyp, NVIDIA, BSE, Endoscopy, NSE, Architecture, Video game, Medical device

This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components.

Key Points: 
  • This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components.
  • The architecture is a scalable platform that supports multiple applications, providing a real-time decision-making tool for the medical fraternity.
  • Developed from the ground up, the architecture boasts an image processing pipeline for noise reduction, edge and contrast enhancement, texture and color enhancement, and speckle correction.
  • “The combination of LTTS’ expertise in medical-device development and NVIDIA’s full-stack edge AI computing platform delivers unprecedented value to the medical technology industry by accelerating the development of AI-enabled, software-defined medical devices,” Shanker Trivedi, Senior Vice President of Enterprise Business, NVIDIA.

Robotic Surgery Pioneer Virtuoso Surgical Awarded $1.8 Million in SBIR Funding

Retrieved on: 
Tuesday, November 14, 2023
Technology, Radiology, Health Technology, Oncology, Other Science, Research, Medical Devices, Hospitals, Clinical Trials, Biotechnology, Health, Robotics, Women, Seniors, Managed Care, Men, Nanotechnology, Science, Consumer, Medical Supplies, FDA, Hardware, Surgery, Sale, Otorhinolaryngology, Virtuoso, Cadaver, Gynaecology, Lead (engineering), Entrepreneurship, VISE, Surgeon, Elective surgery, Bladder cancer, SBIR, FACS, ENT, NIH, Neurosurgery, Cancer, BPH, Endoscopy, Small Business Innovation Research, Doctor of Philosophy, Uterine fibroid, Medical device, MD, Engineering

Medical device company Virtuoso Surgical, Inc. has been awarded a $1.8 million Small Business Innovation Research (SBIR) NIH grant to be received over the next two years.

Key Points: 
  • Medical device company Virtuoso Surgical, Inc. has been awarded a $1.8 million Small Business Innovation Research (SBIR) NIH grant to be received over the next two years.
  • Virtuoso’s robotic surgery system enables a new scale of robotic tools and maneuvers in endoscopic surgery that are not possible using today’s instruments.
  • “We are honored to receive this SBIR Phase II grant as we move toward commercialization of our groundbreaking robotic surgical system ,” said S. Duke Herrell, III, MD, FACS , CEO, Co-Founder and Chief Medical Officer of Virtuoso Surgical.
  • They developed the Virtuoso Surgical system with a design team helmed by COO, Co-founder and Lead Engineer Richard Hendrick, PhD.

OMNIVISION Launches New OVMed® Image Signal Processor for Up to 2MP Medical Endoscope Cameras

Retrieved on: 
Monday, November 13, 2023
Photography, Radiology, Audio, Video, Hardware, Health, Medical Devices, Technology, Semiconductor, OCHSA, EMI, Engineering, Wi-Fi, IEC, Multimedia, ISP, Algorithm, FPGA, ASIC, System, SOC, EMC, MP, Endoscopy, Original equipment manufacturer, Reusability, CMOS, Carbon, MIPI

It supports all OMNIVISION medical image sensors up to 2-megapixel (MP) resolution, including the popular OCHTA , OVM6946 , OCHFA , OCHSA and OCH2B imagers.

Key Points: 
  • It supports all OMNIVISION medical image sensors up to 2-megapixel (MP) resolution, including the popular OCHTA , OVM6946 , OCHFA , OCHSA and OCH2B imagers.
  • The ability to purchase a medical-grade image sensor with wafer-level optics, cable and ISP from one vendor also simplifies the supply chain,” said Richard Yang, senior staff marketing manager, OMNIVISION.
  • The OH0131 kernel features the latest state-of-the-art image pre-processing algorithms supporting brightness, contrast, saturation, sharpness, hue, white balance and gamma adjustment with advanced noise reduction.
  • The OVMed® OH0131 is available now; OMNIVISION plans to put the ISP through IEC 60601 EMC and EMI pre-scan testing.

Global Urology Surgical Instruments Market Expected to Surge at 8% CAGR: Rising Urological Disorders and Advancements Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, November 10, 2023
Surgery, Health, Medical Supplies, Urology, Research, Prevalence, Patient satisfaction, Investment, Minimally invasive procedure, Stryker Corporation, Olympus Corporation, System, Urinary incontinence, Compound annual growth rate, KARL, Ageing, Instrument, Kidney, Growth, Endoscopy, Chronic kidney disease, Patient, Video game, Medical device

The global urology surgical instruments market is poised for significant growth, with a projected Compound Annual Growth Rate (CAGR) of 8% during the forecast period from 2023 to 2031.

Key Points: 
  • The global urology surgical instruments market is poised for significant growth, with a projected Compound Annual Growth Rate (CAGR) of 8% during the forecast period from 2023 to 2031.
  • Urology surgical instruments are crucial in diagnosing and treating urological conditions, and several factors are driving the market's expansion.
  • Rising Prevalence of Urological Disorders: Increasing cases of urological disorders, including kidney stones, urinary incontinence, and prostate disorders, are driving the demand for urology surgical procedures and instruments.
  • Technological Advancements and Innovations: Continuous advancements in urology surgical instruments, including robotic-assisted systems and imaging technologies, are enhancing precision and reducing invasiveness in urological surgeries.

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

Retrieved on: 
Tuesday, December 12, 2023
Identification, Esophageal, Biomedical Research, Risk, Esophagus, Patient, Data analysis, Extrapyramidal system, Triage, Barrett's esophagus, Physician, Archive, Registry, Publication, Medical imaging, Nursing, Lucid, Endoscopy

NEW YORK, Dec. 12, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that three manuscripts providing interim results from the Prospective REView of Esophageal Precancer DetectioN in AT-Risk Patients (PREVENT) Registry, the CLinical Utility of EsoGuard (CLUE) study, and full data from the San Antonio Firefighter study, have been published—the first peer-reviewed publications demonstrating real-world clinical utility of Lucid's EsoGuard® Esophageal DNA test to detect esophageal precancer.

Key Points: 
  • Real-World Experience and Clinical Utility of EsoGuard® – Interim Data from the Lucid Registry .
  • Interim analysis of 409 of 517 enrolled patients with complete clinical utility data in the PREVENT and PREVENT-FF registries of patients undergoing EsoGuard testing by Lucid personnel.
  • "These clinical utility studies, encompassing over 1,000 patients, clearly demonstrate that prescribing physicians are properly leveraging EsoGuard results to guide their medical decision making," said Victoria T. Lee, M.D.
  • "These outstanding clinical utility results complement existing clinical validity data on EsoGuard's unprecedented precancer detection performance.

Medtronic and Cosmo Pharmaceuticals forge ahead in AI-driven care

Retrieved on: 
Monday, December 11, 2023
NYSE, Medtronic, Patient, Fruit, FDA, GI, Caregiver, Partnership, Health, AI, Gastroenterology, Adenoma, Endoscopy, Medical device, Pharmaceutical industry

DUBLIN, Dec. 11, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announces that it has entered into a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals. This AI-driven partnership will further capitalize on the achievements already realized with the GI Genius™ intelligent endoscopy module, offering continued innovation and scalable healthcare advancements for patients and caregivers globally. Through this exclusive global partnership, Medtronic and Cosmo Pharmaceuticals remain committed to revolutionizing endoscopy by harnessing the power of AI to improve patient outcomes. This strategic alliance reinforces Medtronic's position in AI-integrated healthcare solutions and represents a significant leap in incorporating AI into endoscopic care.

Key Points: 
  • Agreement expands partnership between Medtronic and Cosmo Pharmaceuticals, set to transform endoscopy with cutting-edge AI technology
    DUBLIN, Dec. 11, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announces that it has entered into a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals.
  • Through this exclusive global partnership, Medtronic and Cosmo Pharmaceuticals remain committed to revolutionizing endoscopy by harnessing the power of AI to improve patient outcomes.
  • "Our expanded partnership with Cosmo Pharmaceuticals is a strategic milestone in our mission to leverage AI for enhanced patient care," said Geoff Martha, chairman and chief executive officer at Medtronic.
  • Cosmo Pharmaceuticals will continue to be the exclusive manufacturer, granting Medtronic exclusive, global, commercial rights.

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
Thursday, December 7, 2023
Pressure, Nonsteroidal anti-inflammatory drug, Polyp (medicine), AstraZeneca, Inflammation, Face, Budesonide, Omalizumab, CRS, Eosinophilic granulomatosis with polyangiitis, Disease, Network congestion, PROPEL, Sleep apnea, Patient, Snoring, EU4, Sinusitis, Polyp, Allergic rhinitis, Fluticasone, Endoscopy, Smell, Nasal administration, Aspirin, Ibuprofen, Diagnosis, Cystic fibrosis, Tezepelumab, Risk, Growth, Glucocorticoid, Recurrence, Rhinorrhea, Mometasone, Physician, Asthma, LAS, Taste, GSK plc, Paranasal sinuses, Amgen, Pharmaceutical industry, Nursing

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
Thursday, December 7, 2023
Pressure, Nonsteroidal anti-inflammatory drug, Polyp (medicine), AstraZeneca, Inflammation, Face, Budesonide, Omalizumab, CRS, Eosinophilic granulomatosis with polyangiitis, Disease, Network congestion, PROPEL, Sleep apnea, Patient, Snoring, EU4, Sinusitis, Polyp, Allergic rhinitis, Fluticasone, Endoscopy, Smell, Nasal administration, Aspirin, Ibuprofen, Diagnosis, Cystic fibrosis, Tezepelumab, Risk, Growth, Glucocorticoid, Recurrence, Rhinorrhea, Mometasone, Physician, Asthma, LAS, Taste, GSK plc, Paranasal sinuses, Amgen, Pharmaceutical industry, Nursing

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

PeaceHealth Awards Medline Physician Office and Post-acute Prime Vendor Agreements

Retrieved on: 
Wednesday, December 6, 2023
Ambulatory care, PAR, Dermatology, Endoscopy, PeaceHealth, ASC, Hospice, Partnership, Nursing, Online shopping, MEDLINE

Through the agreements, Medline provides an extensive portfolio of medical surgical supplies, equipment and devices to over 400 PeaceHealth clinics – physician office, ambulatory care, community health and home and hospice care -- in Oregon and Washington, with expansion plans for Alaska. Medline resources also help enable PeaceHealth to more easily monitor key metrics, such as item utilization, contract compliance, price accuracy and spend by product categories for these divisions.

Key Points: 
  • NORTHFIELD, Ill., Dec. 6, 2023 /PRNewswire/ -- Building on their longstanding relationship, PeaceHealth recently awarded Medline both its physician office and post-acute care prime vendor agreements.
  • Through the agreements, Medline provides an extensive portfolio of medical surgical supplies, equipment and devices to over 400 PeaceHealth clinics – physician office, ambulatory care, community health and home and hospice care -- in Oregon and Washington, with expansion plans for Alaska.
  • It's all about relationships and these agreements are a win for PeaceHealth and a win for Medline."
  • PeaceHealth also expects its prime vendor partnerships with Medline to help with future affiliate network recruitment.